To amend title XI of the Social Security Act to alter when biosimilar biological products are eligible for price negotiations under the Medicare program.

This bill would change the rules about when biosimilar biological products — which are medicines that are very similar to existing brand-name biological drugs — can have their prices negotiated under Medicare. It would modify the Social Security Act to adjust the timeline or conditions for when these products become eligible for government price negotiations. No official summary is available for this bill.

Your Vote